YF057

YF057 is an orally bioavailable small molecule degrader targeting Signal Transducer and Activator of Transcription 6 (STAT6), currently in preclinical development by InventisBio for the treatment of oncology. STAT6 is a transcription factor that plays a critical role in the signaling pathways of IL-4 and IL-13, which are often implicated in the tumor microenvironment and immune evasion. By utilizing a targeted protein degradation approach, YF057 aims to reduce STAT6 protein levels and activity, potentially overcoming the limitations of traditional inhibitors and providing a novel therapeutic strategy for STAT6-dependent cancers.